AI Rating
7.2
Key Drivers
- Strong margins
- Robust liquidity
- Expensive valuation
AIAI Summary
7.2
IRMD is a strong, debt-free medtech compounder with exceptional margins and cash generation, but the stock's premium multiple means upside now depends on sustaining high-teens-like execution and margin stability—otherwise valuation compression is the main risk.
Quality
ValuationRisk
MedTech
Price Chart
Loading chart...
Financial Metrics
-
Revenue (TTM)-
Net Income (TTM)-
EPS (Q)-
MCAPDeep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
9.0
Key Financial Insights:
- •Strong margins
- •Robust liquidity
- •Expensive valuation
IRMD has excellent margins, cash flow, and liquidity with minimal solvency risk, but its rich valuation limits upside despite improving profitability.
HighQuality
RichValuation
Price Behavior
7.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.
Key Price Behavior Insights:
- •Breakout Confirmed
- •Support Holding
- •Near-Term Extended
IRMD broke out above $94-$96 over the last month to new highs near $100.97, keeping the trend bullish but somewhat stretched near term.
breakout
stretched
Support Level: $94-$96
Resistance Level: $100.97
Sharp climb from the low $91s to near $101 in the last month suggests a stretched short-term move
Sentiment & News
0.0
Similar Companies in Healthcare
Other companies in the same sector with AI ratings
KRYS
Krystal Biotech, Inc.
8.5
Fundamental9.5
Technical7.5
Sentiment7.0
CRMD
CorMedix Inc.
8.1
Fundamental8.8
Technical6.5
Sentiment7.5
ARGX
argenx SE
8.1
Fundamental9.0
Technical6.7
Sentiment7.8
ALNY
Alnylam Pharmaceuticals, Inc.
8.0
Fundamental8.0
Technical6.0
Sentiment7.0
HALO
Halozyme Therapeutics, Inc.
8.0
Fundamental8.0
Technical7.0
Sentiment7.0